Physician profile
Bryan D Hammar
NPI 1841219987
$3,961.02
in general payments reported to CMS, 2019-2025
31 companies · $720 in 2025
The $720 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.22 · 2020: $249 · 2021: $482 · 2022: $749 · 2023: $737 · 2024: $949 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,405.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,863.30 | 2021-2025 | |
| Amgen INC. | $554.96 | 2020-2025 | Otezla, Enbrel, Repatha |
| Sanofi-Aventis U.S. LLC | $188.14 | 2019-2022 | |
| Novo Nordisk INC | $140.28 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $105.92 | 2020-2023 | |
| Vanda Pharmaceuticals INC. | $98.13 | 2024-2025 | Fanapt |
| Lilly USA, LLC | $93.76 | 2021-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $89.72 | 2019-2023 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.82 | 2020-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $76.06 | 2023-2025 | |
| Mylan Specialty L.P. | $68.26 | 2020-2024 | Yupelri |
| Sanofi Pasteur INC. | $66.43 | 2023-2024 | |
| Corium, LLC | $58.34 | 2024-2025 | Azstarys |
| Axsome Therapeutics, INC. | $57.22 | 2023-2025 | Auvelity |
| Amarin Pharma, INC. | $47.52 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $46.97 | 2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.24 | 2024-2025 | Caplyta |
| Astellas Pharma US INC | $34.14 | 2024 | Veozah |
| Genentech USA, INC. | $29.45 | 2020-2022 | |
| Exact Sciences Corporation | $28.80 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $28.52 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals Lp | $27.65 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $23.62 | 2021 | |
| Biogen, INC. | $19.36 | 2021 | |
| Braeburn INC. | $16.36 | 2024 | Brixadi |
| Biohaven Pharmaceutical Holding Company Ltd. | $14.72 | 2022 | |
| Lundbeck LLC | $13.60 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $13.41 | 2025 | Voquezna |
| Boston Scientific Corporation | $11.73 | 2021 | |
| Allergan, INC. | $11.51 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Hammar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.